Table 2.
Human absorbed dose estimates of 177Lu-3PRGD2 obtained from U87MG tumor mice.
| Target Organ | Effective Dose (mSv/MBq) | ||
|---|---|---|---|
| Mean | SD | N | |
| Adrenals | 3.36E-06 | 3.08E-07 | 4 |
| Brain | 2.83E-06 | 5.24E-07 | 4 |
| Breasts | 1.29E-05 | 5.52E-06 | 4 |
| LLI Wall | 3.92E-05 | 3.00E-05 | 4 |
| Small Intestine | 3.34E-06 | 4.02E-06 | 4 |
| Stomach Wall | 2.11E-04 | 1.88E-04 | 4 |
| ULI Wall | 3.46E-06 | 3.25E-06 | 4 |
| Heart Wall | 7.75E-04 | 1.54E-04 | 4 |
| Kidneys | 7.39E-04 | 2.21E-04 | 4 |
| Liver | 7.77E-04 | 1.21E-04 | 4 |
| Lungs | 2.52E-03 | 4.58E-04 | 4 |
| Muscle | 2.20E-06 | 4.73E-07 | 4 |
| Pancreas | 4.18E-06 | 5.26E-07 | 4 |
| Red Marrow | 5.25E-05 | 1.08E-05 | 4 |
| Osteogenic Cells | 8.75E-05 | 3.10E-05 | 4 |
| Skin | 1.86E-06 | 7.74E-07 | 4 |
| Spleen | 5.81E-03 | 1.19E-03 | 4 |
| Thymus | 8.92E-07 | 3.52E-07 | 4 |
| Thyroid | 9.02E-06 | 4.49E-06 | 4 |
| Urinary Bladder Wall | 9.26E-06 | 7.49E-06 | 4 |
| Total Body | 1.35E-02 | 4.49E-03 | 4 |